NextCure signs up to $745 million deal with China's Simcere to develop cancer drug
NextCure said it will gain global rights to the experimental therapy, SIM0505, in all regions except Greater China, where Simcere Zaiming will retain control.
Zaiming is eligible to receive payments throughout the potential development phases, including upfront payment and other milestones up to $745 million, as well as tiered royalties up to double digits on net sales outside China, NextCure added.
Simcere's SIM0505 belongs to a class of drugs known as antibody-drug conjugates (ADCs), which are more targeted than conventional chemotherapy.
These therapies, also known as 'guided missiles', use antibodies to deliver toxic drugs directly to cancer cells, helping to destroy the tumor while leaving healthy cells unharmed.
U.S. drugmakers have been licensing drugs from China for potential new medicines at an accelerating pace, as they look to rebuild pipelines of future products while facing a patent cliff for the older drugs.
The experimental cancer drug is currently being tested in an early-stage trial in China. Initial data from the trial is expected in the first half of next year.
The company expects to begin studying the drug in the U.S. in the third quarter of 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
JD.com faces battle to gain ground in China's instant delivery market
Aug 14 (Reuters) - Chinese e-commerce giant ( opens new tab, is going all out to build its instant-delivery business to diversify revenue, but breaking into the competitive industry is proving difficult. The company has poured billions into JD Takeaway, the food-delivery unit it launched in February, to cut reliance on a core retail business hit by a weak economy and tough competition. Its results on Thursday showed the service has lifted its user base, traffic and revenue, with both quarterly active customer growth and shopping frequency up more than 40%. But it is struggling to take market share from long-established incumbents Meituan ( opens new tab, the industry leader, and Alibaba's ( opens new tab Daily active users in JD's delivery business have fallen steadily since peaking in mid-June, slipping more than 13% week-on-week by July 27 versus a 6% drop and a 1% gain in the previous two weeks, M Science data showed. The data signals "a significant loss of momentum for and likely market share loss", M Science analyst Vinci Zhang said. "Meituan and Alibaba already have considerable domain expertise in food delivery, and I don't think JD has expertise in that area yet. It will be very challenging," Zhang said. food delivery investments have also squeezed profitability. Its adjusted operating margin shrank to 0.3% in the June quarter from 4% a year ago. Meituan's daily orders across food and retail goods reached an all-time high of 120 million. The company holds nearly 70% of the delivery market, Morningstar analysts said in May. Alibaba's Taobao instant commerce business combined with reached 80 million daily orders early in July, with daily active users crossing 200 million. Company executives have warned of fierce competition, with the three companies together pledging nearly 200 billion yuan ($27.87 billion) in recent months to subsidize instant delivery, sparking an "instant retail" price war that has drawn regulatory scrutiny. "The competition started to intensify since July," CEO Sandy Xu said on Thursday, adding the company was focused on improving its platform to attract more users, merchants and riders. Meituan and Alibaba are yet to report quarterly results. ($1 = 7.1773 Chinese yuan renminbi)
Reuters
2 hours ago
- Reuters
Rupee slips; S&P upgrade lends a lifeline ahead of Trump-Putin meet
MUMBAI, Aug 14 (Reuters) - The Indian rupee declined on Thursday with traders treading lightly ahead of the Trump-Putin summit, although S&P's upgrade offered a silver lining. The rupee closed at 87.5500 against the U.S. dollar, softer than Wednesday's close of 87.4400, navigating a choppy session that saw it swing between 87.39 and 87.67. With the focus squarely on the Trump-Putin meet, the S&P's upgrade of India offered a boost to the local currency right when it was grappling with midday pressure. S&P noted that India's robust external position is a key credit strength. It highlighted that current account deficits are likely to remain small over the next few years, while domestic demand stabilises and a weaker rupee boosts competitiveness. The agency further pointed to the rupee's active trading status, noting it accounts for more than 1% of global foreign exchange turnover. "In the shorter term, we may see some relief on the ratings upgrade, but the rupee is still not out of the woods as trade uncertainties persist and broad economic indicators are still weak," said Dilip Parmar, currency analyst at HDFC Securities. The Trump-Putin meeting to discuss the Russia-Ukraine war holds added significance for the rupee. The U.S. president has criticised India's purchase of Russian oil and imposed an extra 25% tariff on its goods effective August 27, doubling the rate to 50% - the highest U.S. tariff on a country alongside Brazil. The currency unit touched 87.8850 last week after Trump's tariffs salvo, with the Reserve Bank of India stepping in to prevent the rupee from breaching the all-time low of 87.95 - a level bankers believe the central bank will continue to defend. Meanwhile, the U.S. dollar index was up 0.1% at 97.835 at 1550 IST.
Reuters
4 hours ago
- Reuters
India wants US ties based on mutual respect, says its arms purchases are on course
NEW DELHI, Aug 14 (Reuters) - India said on Thursday that it hoped relations with the United States would move forward based on mutual respect and shared interests, seeking to temper worries that ties were headed downhill in the aftermath of high tariffs imposed by Washington. A U.S. defence policy team will be in New Delhi this month for talks with Indian officials and its arms purchases from the U.S. are on course despite the strain in ties, the Indian foreign ministry said. A new friendship built between the two countries has hit a rough patch after President Donald Trump raised tariffs on Indian goods to 50% last week from an earlier 25% saying it was a penalty for India's continued imports of Russian oil. New Delhi has accused the U.S. of double standards in singling it out for Russian oil imports and called the tariffs unfair, unjustified and unreasonable. At the same time, it has also indicated that the warming of ties that began at the turn of the century covers a wide range of areas and should not be seen only through the prism of trade, although it hopes that trade talks will continue and result in a deal. "This partnership has weathered several transitions and we hope that the relationship will continue to move forward based on mutual respect and shared interests," Indian foreign ministry spokesperson Randhir Jaiswal told a regular media briefing. Purchases of military equipment from Washington were on course, Jaiswal said, adding that a U.S. defence policy team was expected in Delhi this month. Reuters reported last week that India has put on hold its plans to procure new U.S. weapons and aircraft and that a planned trip to Washington by the Indian defence minister had been cancelled. The Indian government subsequently said reports of a pause in the talks were wrong.
